Metropolis Healthcare Ltd. (METROPOLIS) AI Stock Analysis

• Market Cap: ₹92.88B
• Dividend Yield: 0.21%
• Average Volume (3M): 3.90K
• Price to Earnings (P/E): 60.4
• Beta (1Y): 0.76
• Revenue Growth: 15.41%
• EPS Growth: 5.93%
• Country: IN
• Employees: 4,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 9.25
• Shares Outstanding: 51,831,944
• 10 Day Avg. Volume: 4,604
• 30 Day Avg. Volume: 3,901
• PEG Ratio: 4.05
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 5.90
• P/FCF Ratio: 35.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 40.53
• Revenue Forecast (FY): ₹16.53B

• Rating: 61 Neutral
• Price Target: ₹1,890.00 ▼(-2.06% Downside)
• Action: Reiterated Date: 10/10/25
• Date: Action: Reiterated 10/10/25

Metropolis Healthcare Ltd. has a strong financial foundation, which is the most significant factor in its overall score. However, technical analysis indicates potential short-term weakness, and the high P/E ratio suggests overvaluation, which detracts from the stock's attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

High Profitability

Sustained high gross and healthy EBITDA/net margins indicate durable pricing power and efficient lab operations. Strong margins support reinvestment, margin resilience through cost absorption, and long-term profitability across routine and specialized diagnostic services.

Robust Cash Generation

Consistent operating and free cash flow conversion demonstrates the company converts earnings into cash reliably. This cash strength funds network expansion, capex for centralized labs, and potential shareholder returns without relying on external financing.

Strong Balance Sheet

Low leverage and a high equity ratio provide financial flexibility and lower solvency risk, enabling investment in lab capacity and technology. A conservative capital structure supports steady operations during cycles and reduces refinancing and interest-rate vulnerability.

Negative Factors

Franchise/Partner Reliance

Dependence on franchise and collection partners creates durable operational complexity and variability in unit economics. Revenue-sharing and commission arrangements can constrain margin expansion and make service quality and volume growth more dependent on third-party execution.

EPS Growth Lagging Revenue

Revenue growth outpacing EPS growth over recent periods can signal reinvestment, margin pressure, or dilution that limits earnings per share improvement. If persistent, this reduces per-share profitability gains despite higher top-line volumes.

Moderate ROE vs. Low Leverage

Given low leverage and high margins, a mid-teens ROE suggests capital is not being deployed to generate higher shareholder returns. This structural limitation may reflect conservative strategy or returns constraints in the core diagnostics market.

Metropolis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.

How the Company Makes Money

Metropolis Healthcare generates revenue primarily through its diagnostic testing services, which include a wide array of laboratory tests ranging from routine blood tests to specialized genetic testing. The company earns money by charging fees for these tests conducted in its laboratories. Additionally, Metropolis has established partnerships with hospitals, clinics, and healthcare providers, which contribute significantly to its revenue by offering bundled services and referral business. The company also generates income through its health packages and preventive health check-ups, aimed at promoting overall wellness among clients. Furthermore, Metropolis leverages technology through its online platforms, allowing customers to book tests and access results digitally, which helps in enhancing customer engagement and driving additional revenue streams.

Metropolis Healthcare Ltd. Financial Statement Overview

Summary

Metropolis Healthcare Ltd. exhibits strong financial health across all verticals. The income statement reflects robust revenue and profit growth, indicating competitive strength and operational efficiency. The balance sheet is solid with low leverage and a strong equity base, reducing financial risk. The cash flow statement underscores efficient cash conversion and growth, supporting expansion and shareholder value.

Income Statement

Metropolis Healthcare Ltd. shows strong performance with a consistent increase in revenue and profitability. The gross profit margin is impressive at 79.8% for 2025, indicating effective cost management. The net profit margin has also improved, reaching 10.9% in 2025, reflecting enhanced operational efficiency. EBIT and EBITDA margins stand at 55.5% and 22.8% respectively, demonstrating robust profitability. Revenue growth of 10.2% from 2024 to 2025 further underscores the company's solid market position and growth potential.

Balance Sheet

The balance sheet of Metropolis Healthcare Ltd. is strong, supported by a healthy equity ratio of 71.3% in 2025, indicating a solid capital structure. The debt-to-equity ratio is manageable at 0.15, reflecting low leverage and thus reduced financial risk. Return on equity is 10.9%, highlighting efficient use of shareholder funds. Overall, the company maintains a stable and low-risk financial position, which provides a strong foundation for future growth.

Cash Flow

Cash flow generation is robust, with a free cash flow growth rate of 9.5% from 2024 to 2025, indicating efficient operations and sound financial health. The operating cash flow to net income ratio is strong at 1.81, showing that the company generates ample cash relative to its profitability. Free cash flow to net income ratio is high at 1.51, demonstrating a solid ability to convert profits into cash. Overall, Metropolis Healthcare Ltd. showcases a strong cash flow profile, facilitating business expansion and shareholder returns.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	14.04B	13.31B	12.08B	11.48B	12.28B	9.98B
Gross Profit	10.85B	10.28B	9.38B	8.74B	9.31B	7.28B
EBITDA	2.43B	2.16B	2.18B	2.36B	3.07B	2.63B
Net Income	1.52B	1.45B	1.28B	1.43B	2.14B	1.83B
Balance Sheet
Total Assets	0.00	18.67B	15.55B	15.02B	15.30B	10.04B
Cash, Cash Equivalents and Short-Term Investments	1.18B	1.18B	1.24B	1.20B	1.81B	4.20B
Total Debt	0.00	2.04B	1.97B	2.66B	3.79B	1.12B
Total Liabilities	-13.35B	5.33B	4.56B	5.11B	6.42B	2.96B
Stockholders Equity	13.35B	13.31B	10.96B	9.88B	8.86B	7.07B
Cash Flow
Free Cash Flow	0.00	2.19B	2.00B	1.94B	2.23B	2.21B
Operating Cash Flow	0.00	2.63B	2.64B	2.47B	2.53B	2.49B
Investing Cash Flow	0.00	-2.01B	-894.12M	467.94M	-7.38B	617.01M
Financing Cash Flow	0.00	-866.34M	-1.81B	-2.92B	1.63B	-326.90M

Metropolis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1929.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Negative. The current price of 1929.7 is above the 20-day moving average (MA) of 1922.63, above the 50-day MA of 1910.60, and above the 200-day MA of 1925.64, indicating a bearish trend. The MACD of -19.95 indicates Positive momentum. The RSI at 34.73 is Neutral, neither overbought nor oversold. The STOCH value of 15.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:METROPOLIS.

Metropolis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹98.35B	63.11	―	0.20%	16.71%	13.92%
THYROCARE	69 Neutral	₹59.59B	61.22	―	0.68%	22.36%	52.00%
HCG	67 Neutral	₹81.00B	-247.47	―	―	17.58%	-38.20%
LALPATHLAB	66 Neutral	₹224.14B	68.44	―	0.89%	10.80%	32.79%
KRSNAA	62 Neutral	₹19.83B	38.37	―	0.38%	11.51%	21.56%
METROPOLIS	61 Neutral	₹92.88B	60.35	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Metropolis Healthcare Ltd. Corporate Events

Metropolis Healthcare Clears Q3 FY26 Results, Announces 3:1 Bonus Issue and Internal Business Transfer

Metropolis Healthcare Limited’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with the limited review report from its statutory auditors indicating no material misstatements, and has made these results available on its website. The board also recommended a substantial bonus issue of equity shares in a 3:1 ratio, signalling an effort to reward shareholders and enhance liquidity, and approved the sale of its External Quality Assessment Services division to wholly owned subsidiary Metropolis Quality Solutions Private Limited via a slump sale of up to INR 1.25 crore, a move that restructures its quality assessment business under a dedicated entity and may streamline operations within the group.

Metropolis Healthcare Schedules Q3 FY26 Earnings Call for February 5

Metropolis Healthcare Limited has announced that it will hold its Q3 FY26 earnings conference call on February 5, 2026, at 9:00 a.m. IST, organized by ICICI Securities, to discuss its financial results for the quarter ended December 31, 2025. The call will feature senior leadership including Chairperson and Whole-time Director Ameera Shah, Managing Director Surendran Chemmenkotil, Chief Financial Officer Sameer Patel and Chief Business Development Officer Avadhut Joshi, underscoring the importance of the upcoming results discussion for investors and other stakeholders tracking the company’s financial performance and strategic direction.